America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein that, for example, acts like a ‘blizzard’ that can block the main center of the airway and thus only cancer. The movement of planes carrying sales will stop.
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub. Stops all traffic of aircraft carrying cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What is the mechanism of action for the AOH1996 molecule in targeting cancer cells?
**Interview with Dr. Linda Malkas, City of Hope Hospital**
**Editor:** Thank you for joining us today, Dr. Malkas. Your recent research on the AOH1996 molecule sounds groundbreaking. Can you explain how this new drug works to target cancer cells?
**Dr. Malkas:** Thank you for having me. AOH1996 is designed to specifically target the cancer variant of a protein known as PCNA, which plays a crucial role in DNA replication and tumor growth. You can think of PCNA like a major airline terminal, where cancer cells have unique mutations allowing them to multiply unchecked. Our drug acts like a blizzard, selectively blocking these routes and halting the growth of tumors effectively while sparing normal cells.
**Editor:** That’s a fascinating analogy. You mentioned that this drug has been effective in treating various types of cancer. Can you elaborate on the types of cancers that have responded well to this treatment?
**Dr. Malkas:** Absolutely. In clinical research, AOH1996 has shown promise in treating breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We tested it on over 70 cancer cell lines, and the results were encouraging. The drug selectively killed cancer cells by disrupting their normal reproductive cycle, which is crucial for their survival.
**Editor:** What are the next steps for this research?
**Dr. Malkas:** The next phase involves advancing our findings into human clinical trials. We are excited about the potential of AOH1996 to impact cancer treatment significantly, and these trials will help us understand how well it works in patients.
**Editor:** It’s inspiring to hear how your work is making headway in the fight against cancer. Is there anything else you’d like our readers to know about this research?
**Dr. Malkas:** Yes, I’d like to emphasize that this research is a culmination of nearly two decades of work by our dedicated team at City of Hope. Our goal is to provide targeted and effective treatments for cancer patients, reducing the side effects associated with traditional chemotherapy. We’re hopeful that AOH1996 can lead to better outcomes in cancer therapy.
**Editor:** Thank you, Dr. Malkas. Your insights into this innovative research are greatly appreciated. We look forward to following the progress of AOH1996 in clinical trials.
**Dr. Malkas:** Thank you for the opportunity to share our work!
